Customize your JAMA Network experience by selecting one or more topics from the list below.
On June 21, 2007, CDC's Investigational New Drug Application (IND) for intravenous artesunate went into effect. This IND allows for use of an investigational antimalarial medication (intravenous artesunate) under a protocol entitled “Intravenous Artesunate for Treatment of Severe Malaria in the United States.” Intravenous artesunate can be used only under the provisions of this IND protocol because it is not a drug approved by the Food and Drug Administration (FDA). Artesunate is in the class of medications known as artemisinins, which are derivatives from “quing hao,” or sweet wormwood plant (Artemisia annua). Only the CDC Drug Service and CDC Quarantine Stations will be permitted to release the medication for use under this IND protocol.
Notice to Readers: New Medication for Severe Malaria Available Under an Investigational New Drug Protocol. JAMA. 2007;298(10):1156. doi:10.1001/jama.298.10.1156
Create a personal account or sign in to: